8-K: Lifeward Launches ReWalk 7 Personal Exoskeleton in the U.S., Offering Enhanced Mobility for Individuals with Spinal Cord Injury

Lifeward Ltd. announces the U.S. national launch of the ReWalk 7 Personal Exoskeleton, featuring new and improved functionalities for individuals with spinal cord injury.

Summary

• Lifeward Ltd. has launched the ReWalk 7 Personal Exoskeleton in the U.S.
• The ReWalk 7 is the seventh generation of Lifeward's personal exoskeleton technology.
• It includes new features like cloud connectivity and customizable walking speeds.
• The device aims to provide a more functional and personalized walking experience for individuals with spinal cord injury (SCI).
• The ReWalk 7 was developed with feedback from clinicians and patients.
• The FDA clearance process involved gathering feedback from over two dozen end users and physical therapists.
• The ReWalk 7 is now available for purchase in the U.S. for personal and clinical use.
• In 2023, the ReWalk 6.0 system was updated to allow users to navigate stairs and curbs.
• In 2024, CMS finalized a Medicare reimbursement pathway for personal exoskeleton use.

Sentiment

Score: 8

Explanation: The announcement is positive due to the launch of a new product with enhanced features and FDA clearance, indicating potential revenue growth and market expansion. The mention of Medicare reimbursement further supports a positive outlook.

Positives

• The ReWalk 7 offers smoother movement with customizable walking speeds.
• Crutch Control allows users to stand, walk, select speeds, and stop with the touch of a button.
• The Wrist Control smartwatch and MyReWalk mobile app enable users to select operation modes, set goals, and track usage.
• The device has improved battery life and seamless activation of stairs and curbs.
• The therapist handheld device and click-to-stop control allow for safer, more effective training.

Risks

• Acceptance of the ReWalk 7 by healthcare professionals and patients is uncertain.
• The company's ability to have sufficient funds to meet certain future capital requirements could impair the Company's efforts to develop and commercialize existing and new products.
• The company's ability to achieve reimbursement from third-party payors, including CMS, for its products is a risk.
• The company's ability to maintain adequate protection of its intellectual property and to avoid violation of the intellectual property rights of others is a risk.
• The risk of a cybersecurity attack or breach of the Company's IT systems significantly disrupting its business operations is a risk.

Future Outlook

The company anticipates that the ReWalk 7 will provide paralyzed individuals across the country with a new option for integrating walking into everyday life.

Management Comments

• Larry Jasinski, CEO of Lifeward, stated that the ReWalk 7 is optimized for real-world use with an unmatched user experience and freedom of movement.
• Jill Butler, PT, DPT, NCS, Director of Clinical Development for Lifeward, noted that therapists found the handheld device would make training sessions easier and ReWalk users were excited about the enhanced level of confidence and control.

Industry Context

This announcement positions Lifeward as a leader in the exoskeleton market, competing with other companies offering similar technologies for rehabilitation and mobility assistance. The availability of Medicare reimbursement is a significant factor in expanding market access.

Comparison to Industry Standards

• The ReWalk 7's features, such as customizable walking speeds and cloud connectivity, align with the industry's trend towards more personalized and data-driven rehabilitation solutions.
• Companies like Ekso Bionics and Cyberdyne also offer exoskeletons, but the ReWalk 7's focus on user feedback and real-world usability may differentiate it.
• The availability of Medicare reimbursement, similar to other advanced medical devices, is crucial for market adoption and aligns with industry standards for accessibility.

Stakeholder Impact

• Shareholders may see increased value due to potential revenue growth.
• Employees may benefit from increased job security and opportunities.
• Customers (individuals with SCI) will have access to an improved mobility solution.
• Suppliers may see increased demand for components used in the ReWalk 7.
• Creditors may view the company as a lower risk due to potential revenue growth.

Next Steps

• Lifeward will begin sales of ReWalk 7 in the U.S.
• The company will continue to gather feedback from clinicians and users to further optimize the device.
• Lifeward will focus on expanding access to the ReWalk Exoskeleton for more individuals living with SCI.

Key Dates

Keywords

ReWalk 7, exoskeleton, spinal cord injury, Lifeward, medical technology, rehabilitation, FDA clearance, CMS reimbursement